Table 1.
Demographics details of eligible patients
| Characteristics (n = 11) | Median | N (%) |
|---|---|---|
| Age (years) | 57 (37–69) | – |
| Male | – | 8 (72.7) |
| Female | 3 (27.2) | |
| Hb (g/dl) | 7.8 (5.4–10.7) | – |
| TLC (/cumm) | 27,730 (11,500–98,200) | – |
| Platelets (/cumm) | 80,000 (8000–131,000) | – |
| Albumin (gm/dl) | 3.4 (2.2–4.4) | – |
| Creatinine (mg/dl) | 1.8 (0.8–8.1) | – |
| B2-microglobulin (mg/ml) | 9.3 (5.2–34.1) | – |
| Peripheral plasma cells (%) | 43 (22–91) | – |
| Bone marrow plasma CELLS (%) | 74 (15–100) | – |
| Serum protein electrophoresis (SPEP) (gm/dl) | 3.3 (0–7.3) | – |
| Performance status (ECOG) | ||
| Score-1 | 7 (63.6) | |
| Score-2 | 3 (27.2) | |
| Score-3 | 1 (09) | |
| 24 h Urine Protein (gm/24 h) |
0.4 (0.09–3.2) Nil in n = 2 patients |
– |
| Uric Acid (mg/dl) | 10.9 (5.7–21.4) | – |
| LDH (U/L) | 434 (106–1531) | – |
| Hepatomegaly | – | 2 (18.1) |
| Splenomegaly | – | 3 (27.2) |
| Extramedullary involvement | – | 2 (18.1) |
| Bony lesions present | – | 8 (72.7) |
| ISS staging | – | |
| ISS-1 | 0 | |
| ISS-2 | 1 (09) | |
| ISS-3 | 9 (81.1) | |
| Not available | 1 (09) | |
| Subtype | – | 3 (27.2) |
| IgG | 2 (18.1) | |
| Light chain | 6 (54.5) | |
| Not available | ||
| FISH (tested for del17p; t(14;20); t(14;16); t(4;14); del 13q) | 3 patients (27.2) | |
| Negative | 1/3 | |
| Positive for del 13q14.3, del 17p13.1, t(4;14) | 1/3 | |
| Positive for del 17p13.1, t(4;14) | 1/3 | |
| Response to chemotherapy (N = 10) (post 2-4 cycles of IMiDs + PIs chemotherapy) | – | |
| Complete response (CR)/very good partial response (VGPR) | 6 (60) | |
| Partial response (PR) | 1 (10) | |
| Stable disease (SD) | 1 (10) | |
| Progressive disease (PD) | 2 (20) | |